Page last updated: 2024-12-08
nsc 638718
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
ecteinascidin 729: a complex structure that includes isoquinolines joined by a cyclic ester; Guanine N2 alkylator with potent antiproliferative activity; a marine natural product from Ecteinascidia turbinata; metabolite of ecteinascidin-743 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 368263 |
| CHEMBL ID | 1998895 |
| MeSH ID | M0263498 |
Synonyms (7)
| Synonym |
|---|
| ecteinascidin 729 |
| NSC638718 , |
| nsc-638718 |
| NCI60_012920 |
| CHEMBL1998895 |
| et-729 |
| [(1s,12s,26s)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21-dimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2h-isoquinoline]-22-yl] acetate |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Intraperitoneal bioavailability varied over a wide range (20-91%)." | ( Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. Ames, MM; Reid, JM; Walker, DL, 1996) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (20.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||